Frequently Asked Questions
What is the purpose of the SURF302 trial?
SURF302 is studying dabogratinib, an investigational oral medication, to see if it can safely and effectively treat FGFR3-altered intermediate-risk non–muscle invasive bladder cancer.
What makes dabogratinib different from other treatments?
Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for this condition. Other treatments often involve bladder infusions or injections, while dabogratinib is taken as a daily tablet.
Who can join the trial?
Adults with low-grade, FGFR3-altered intermediate-risk NMIBC may be eligible.
What does “FGFR3-altered” mean?
Some bladder cancers have a change (or alteration) in a gene called FGFR3. This change helps the cancer grow. Dabogratinib is designed to specifically target that change.
Will I need to stay in the hospital to take part?
No. Dabogratinib is taken at home once a day as a tablet. You will need to visit the study clinic regularly for check-ups and monitoring.
How many people will be in this study?
The study plans to enroll up to 90 participants at sites primarily in the United States.
What are the potential benefits?
Dabogratinib is investigational, which means its benefits and risks are still being studied. Participants may benefit if the drug works against their cancer, but there is no guarantee of benefit.
What are the risks?
Like all medicines, dabogratinib may have side effects. The study clinic will explain potential risks and closely monitor participants to ensure safety.
How can I learn more or see if I qualify?
Talk to your doctor about the SURF302 trial or contact a Tyra study representative at tyraclinicaltrials@tyra.bio. You can also visit https://clinicaltrials.gov/study/NCT06995677 for more details.
Talk to your doctor about the SURF302 trial or contact a Tyra study representative at tyraclinicaltrials@tyra.bio. You can also visit clinicaltrials.gov for more details.
